Live Breaking News & Updates on Coreyj Langer

Stay updated with breaking news from Coreyj langer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC

Corey J. Langer, MD, outlines the prevalence of BRAF mutations in NSCLC and looked ahead to where the development pipeline of agents for the treatment of patients with BRAF-mutated NSCLC is headed. ....

United States , University Of Pennsylvania , Coreyj Langer , International Lung Cancer Congress , Hospital Of The University Pennsylvania , Abramson Cancer Center , Annual International Lung Cancer Congress , Raf V600 Nsclc , Phase 2 Pharos Trial Nct03915951 ,

Dr Langer on Encorafenib Plus Binimetinib in BRAF V600E–Mutant NSCLC

Dr Langer on Encorafenib Plus Binimetinib in BRAF V600E–Mutant NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Coreyj Langer , Gregoryj Riely , Hospital Of The University Pennsylvania , Memorial Sloan Kettering Cancer Center , Thoracic Oncology , Penn Medicine ,

Immunotherapy alone extended life for metastatic lung cancer patients with KRAS mutation


 E-Mail
IMAGE: Charu Aggarwal, MD, MPH (top), Ronac Mamtani, MD, (bottom left), and Lova Sun, MD.
view more 
Credit: Penn Medicine
PHILADELPHIA Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the
Abramson Cancer Center at the University of Pennsylvania.
In a new study published online today in
JAMA Oncology, researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated with immunotherapy alone, compared to patients without this mutation. This survival difference by KRAS status was not seen, however, in patients treated with both chemotherapy and immunotherapy, suggesting combination therapy for patients without the mutation may be preferred. ....

University Of Pennsylvania , United States , Charu Aggarwal , Lova Sun , Rogerb Cohen , Coreyj Langer , Ronac Mamtani , Perelman School Of Medicine , Abramson Cancer Center , Flatiron Health , Perelman School , Associate Professor , Lung Cancer Excellence , Miles Tan , Medicine Health , Clinical Trials , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , ஒன்றுபட்டது மாநிலங்களில் , லோவா சூரியன் , பெரல்மேன் பள்ளி ஆஃப் மருந்து , பிளாட்டிரான் ஆரோக்கியம் , பெரல்மேன் பள்ளி , இணை ப்ரொஃபெஸர் , நுரையீரல் புற்றுநோய் சிறப்பானது , மருந்து ஆரோக்கியம் ,